An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis

No abstract is available for this paper.

• Publication year

  2018

• Venue

  CNS Drugs

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40263-018-0496-6PMID 29508244
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• European Committee for Treatment and Research in Multiple Sclerosis

  2019cited by this paper
• Antenatal ultrasound screening using check list before delivery for predicting a non-reassuring fetal status during labor

  2018cited by this paper
• Multiple sclerosis in pregnancy: prevalence, sociodemographic features, and obstetrical outcomes

  2018cited by this paper
• Long-term exposure to natalizumab during pregnancy - a prospective case series from the German Multiple Sclerosis and Pregnancy Registry

  2017cited by this paper
• Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database.

  2017influential reference
• Long-term exposure to natalizumab during pregnancy – a prospective case series from the German Multiple Sclerosis and Pregnancy Registry (P2.101)

  2017cited by this paper
• Disease activity during pregnancy and pregnancy outcomes in patients with multiple sclerosis treated with Alemtuzumab – A case series from the German MS and Pregnancy Registry (P1.367)

  2017cited by this paper
• Outcomes following natalizumab exposure throughout pregnancy in patients with relapsing multiple sclerosis (RMS) or Crohn’s disease (P1.362)

  2017cited by this paper
• Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy.

  2017cited by this paper
• Glatiramer acetate during early pregnancy: A prospective cohort study

  2016cited by this paper
• Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery.

  2016cited by this paper
• Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre study

  2016cited by this paper
• Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study

  2016cited by this paper
• Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

  2016cited by this paper
• Disease-Modifying Drug Possibly Linked to Placental Insufficiency: Severe placental complications in a pregnant woman with multiple sclerosis.

  2016cited by this paper
• Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks

  2016influential reference
• Risk of relapse after natalizumab withdrawal

  2016cited by this paper
• Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

  2016influential reference
• Management of Multiple Sclerosis in the Breastfeeding Mother

  2016cited by this paper
• Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

  2016cited by this paper
• Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis

  2016cited by this paper
• Disease course during pregnancy in patients with highly active multiple sclerosis

  2016cited by this paper
• Pregnancy and Fetal Outcomes after In Utero Exposure to Natalizumab in Patients with Multiple Sclerosis: A Prospective, Nation-Wide, Controlled Study (S24.006)

  2016cited by this paper
• Pregnancy Outcomes in Patients with RRMS Who Received Alemtuzumab in the Clinical Development Program (S24.008)

  2016cited by this paper
• Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis

  2016cited by this paper
• The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis

  2016cited by this paper
• Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses.

  2015cited by this paper
• MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

  2015cited by this paper
• Transfer of Natalizumab into Breast Milk in a Mother with Multiple Sclerosis

  2015cited by this paper
• Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis

  2015cited by this paper
• Natalizumab continuation during pregnancy in a patient with previous severe IRIS syndrome.

  2015cited by this paper
• An overview of pregnancy‐related issues in patients with multiple sclerosis

  2015cited by this paper
• Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis

  2015cited by this paper
• Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

  2015influential reference
• The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS).

  2015cited by this paper
• Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing–remitting multiple sclerosis three months after childbirth

  2015cited by this paper
• Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program

  2015cited by this paper
• Fecundity in women with multiple sclerosis: an observational mono-centric study

  2015cited by this paper
• Pregnancy does not prevent disease re-activation after natalizumab suspension in patients with multiple sclerosis (S20.003)

  2015cited by this paper
• Postpartum Treatment With Immunoglobulin Does Not Prevent Relapses of Multiple Sclerosis in the Mother

  2015cited by this paper
• Multiple sclerosis and pregnancy in the 'treatment era'

  2015influential reference
• Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

  2015cited by this paper
• Serum anti-Müllerian hormone levels in reproductive-age women with relapsing–remitting multiple sclerosis

  2015cited by this paper
• An overview of upcoming changes in pregnancy and lactation labeling information

  2015cited by this paper
• Parity Associated with Long-Term Disease Progression in Women with Multiple Sclerosis

  2014cited by this paper
• Pregnancy in Multiple Sclerosis

  2014cited by this paper
• Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study

  2014cited by this paper
• Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events

  2014cited by this paper
• Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

  2014cited by this paper
• MS disease activity in RESTORE

  2014cited by this paper
• Management of Multiple Sclerosis During Pregnancy and the Reproductive Years: A Systematic Review

  2014influential reference
• Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation

  2014cited by this paper
• One can prevent post-partum MS relapses by exclusive breast feeding: Yes

  2013cited by this paper
• Cumulative data on pregnancy outcomes after exposure to fingolimod and in comparison with the general population

  2013cited by this paper
• Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

  2013cited by this paper
• Sex and gender issues in multiple sclerosis

  2013cited by this paper
• Tadpole pupil

  2013influential reference
• One can prevent post-partum MS relapses by exclusive breast feeding: No

  2013cited by this paper
• Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis

  2012cited by this paper
• Multiple sclerosis and pregnancy: experience from a nationwide database in Germany

  2012cited by this paper
• Disease-modifying drugs for multiple sclerosis in pregnancy

  2012cited by this paper
• Breastfeeding and multiple sclerosis relapses: a meta-analysis

  2012cited by this paper
• Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

  2011cited by this paper
• Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

  2011cited by this paper
• Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

  2011cited by this paper
• Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency

  2010cited by this paper
• Immunomodulation and postpartum relapses in patients with multiple sclerosis

  2009cited by this paper
• Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study

  2009cited by this paper
• Gender and sex hormones in multiple sclerosis pathology and therapy.

  2009cited by this paper
• A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis

  2007cited by this paper
• Glatiramer acetate: mechanisms of action in multiple sclerosis.

  2007cited by this paper
• Fertility in patients with multiple sclerosis: current knowledge and future perspectives

  2006cited by this paper
• Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis

  2004cited by this paper
• The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention.

  2003cited by this paper
• Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

  1999influential reference
• Rate of Pregnancy-Related Relapse in Multiple Sclerosis

  1998cited by this paper

• Meta-synthesis of the motherhood-related needs of women with multiple sclerosis

  2024cites this paper
• Understanding the meaning of the lived experience “maternal role” in women with multiple sclerosis and planning a supportive program: a combined exploratory study protocol

  2024cites this paper
• Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy

  2022cites this paper
• Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies

  2021cites this paper
• Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies

  2021cites this paper
• Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations

  2020cites this paper
• Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis.

  2020cites this paper
• Dynamic Balance of Microglia and Astrocytes Involved in the Remyelinating Effect of Ginkgolide B

  2020cites this paper
• Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry

  2020cites this paper
• Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure

  2020cites this paper
• Pregnancy with multiple sclerosis.

  2020cites this paper
• Long-term drug treatment in multiple sclerosis: safety success and concerns

  2020cites this paper
• B cell depletion and pregnancy: Review and applications for MS treatment.

  2019cites this paper
• Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review.

  2019cites this paper
• Women’s Health: Contemporary Management of MS in Pregnancy and Post-Partum

  2019influential citation
• Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero

  2019cites this paper
• Managing Risks with Immune Therapies in Multiple Sclerosis

  2019cites this paper
• Disease-modifying therapies for multiple sclerosis

  2018cites this paper
• Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children

  2018cites this paper